Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026)

Fortrea Holdings (FTRE) posted Cash from Investing Activities of -$8.0 million for Q1 2026, down 6.67% on a QoQ basis from -$7.5 million in Q4 2025, and down 149.69% year-over-year from $16.1 million in Q1 2025.

Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026) Analysis & Trends

Fortrea Holdings' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 149.69% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.7 million (down 103.5% YoY) and the FY2025 annual result came in at $14.4 million, down 94.28% from the prior year.
  • Cash from Investing Activities was -$8.0 million for Q1 2026 at Fortrea Holdings, down from -$7.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $265.4 million in Q2 2024 and bottomed at -$18.4 million in Q4 2022.
  • A 5-year average of $12.7 million and a median of -$8.0 million in 2026 frame the typical range for Cash from Investing Activities.
  • Peak annual rise in Cash from Investing Activities reached 2953.76% in 2024, while the deepest fall reached 400.0% in 2024.
  • Fortrea Holdings' Cash from Investing Activities stood at -$18.4 million in 2022, then soared by 51.09% to -$9.0 million in 2023, then surged by 138.89% to $3.5 million in 2024, then tumbled by 314.29% to -$7.5 million in 2025, then declined by 6.67% to -$8.0 million in 2026.
  • Business Quant data shows FTRE's Cash from Investing Activities at -$8.0 million in Q1 2026, -$7.5 million in Q4 2025, and $13.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,921.77 Bn 66,921.49 Bn - -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.57 Bn 466.77 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 122.01 Bn 114.76 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn -25.54 Mn
10 Fortrea Holdings 1.81 Bn 1.67 Bn 123.60 Mn -8.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.00 Mn
Mar 31, 2026 -8.00 Mn
Dec 31, 2025 -7.50 Mn
Dec 31, 2025 -7.50 Mn
Sep 30, 2025 13.30 Mn
Sep 30, 2025 13.30 Mn
Jun 30, 2025 -7.50 Mn
Jun 30, 2025 -7.50 Mn
Mar 31, 2025 16.10 Mn
Mar 31, 2025 16.10 Mn
Dec 31, 2024 3.50 Mn
Dec 31, 2024 3.50 Mn
Sep 30, 2024 -8.10 Mn
Sep 30, 2024 -8.10 Mn
Jun 30, 2024 265.40 Mn
Jun 30, 2024 265.40 Mn
Mar 31, 2024 -9.20 Mn
Mar 31, 2024 -9.20 Mn
Dec 31, 2023 -9.00 Mn
Dec 31, 2023 -9.00 Mn